Cargando…
Repurposing Tecfidera for cancer
Autores principales: | Booth, Laurence, Malkin, Mark, Dent, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993329/ https://www.ncbi.nlm.nih.gov/pubmed/27429364 http://dx.doi.org/10.18632/aging.101001 |
Ejemplares similares
-
Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera
por: Poganik, Jesse R., et al.
Publicado: (2021) -
Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016) -
A retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis during and after Tecfidera® treatment
por: Baeva, Maria-Elizabeth, et al.
Publicado: (2021) -
Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014) -
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)